Amanda Abuaf, MD
Neurology · Madison, WINPI 1225415011
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,910 of the $11,000 with a category attached, or 71.9%. Genentech USA, Inc. accounts for 66.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $7,086 and has fallen 66.7% since, to $2,359 in 2025. Among neurology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $407.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$7K
- TG Therapeutics, Inc.$2K
- AstraZeneca$621
- Novartis$303
- EMD Serono, Inc.$231
- Biogen$125
- plus $166 from 2 others
What the payments were for
- Consulting fees$7,91072%
- Travel & lodging$1,0129%
- Food & beverage$2,07819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 9 | $7,273 |
| TG Therapeutics, Inc. | 2 | $2,281 |
| AstraZeneca | 6 | $621 |
| Novartis | 3 | $303 |
| EMD Serono, Inc. | 4 | $231 |
| Biogen | 1 | $125 |
| Sanofi | 1 | $125 |
| Bristol Myers Squibb | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,000 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 32 | $333,691 |
| BetaseronInterferon Beta-1b | 12 | $134,252 |
| GlatopaGlatiramer Acetate | 22 | $46,277 |
| Teriflunomide | 14 | $38,040 |
| FingolimodFingolimod Hcl | 24 | $7,011 |
| Dimethyl Fumarate | 11 | $2,287 |
| Baclofen | 73 | $1,432 |
| Gabapentin | 80 | $1,422 |
| Duloxetine Hcl | 23 | $669 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $367 |
| Modafinil | 18 | $294 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 14 | $202 |
| Prednisone | 11 | $150 |
| Pregabalin | 20 | $146 |
| Diazepam | 29 | $127 |
Paid to pharmacies, not to this prescriber.
Other neurology in Madison
- Michael SnyderMadison$284K
- Kelsey GageschMadison$60K
- Brian NagleMadison$25K
- Michael FruchtMadison$22K
- Vanesa BotsfordMadison$11K
- Christopher LuzzioMadison$9K
- Ankush BhatiaMadison$7K
- Rama MagantiMadison$6K
- Elizabeth FeltonMadison$5K
- Bhupendra KhatriMilwaukee$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.